Related Experiment Video
Updated: Jan 19, 2026

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
Published on: June 21, 2018
A Mendelian randomization study of IL6 signaling in cardiovascular diseases, immune-related disorders and longevity
Mickael Rosa1, Arnaud Chignon1, Zhonglin Li1
11Laboratory of Cardiovascular Pathobiology, Quebec Heart and Lung Institute/Research Center, Department of Surgery, Laval University, Quebec, Canada.
Insights
Reduced IL6 signaling, indicated by soluble IL6 receptor (sIL6R), may lower cardiovascular disease risk and increase longevity. However, this reduction is linked to a higher risk of atopic conditions like asthma.
Area of Science:
- Genetics and Molecular Biology
- Immunology
- Cardiovascular Medicine
Background:
- Inflammation is increasingly recognized as a key factor in the development of various cardiovascular diseases (CVDs).
- The soluble IL6 receptor (sIL6R) acts as a negative regulator of IL6 signaling, a pathway implicated in inflammatory processes.
- Understanding the causal relationships between sIL6R, IL6 signaling, and disease is crucial for therapeutic development.
Purpose of the Study:
- To investigate the causal inference between plasma levels of soluble IL6 receptor (sIL6R) and the risk of cardiovascular and immune-related disorders.
- To explore the association of genetically determined sIL6R levels with longevity.
- To correlate gene expression data with Mendelian randomization findings to validate IL6 signaling effects.
Main Methods:
- Mendelian randomization (MR) analysis using multiple instrumental variables to assess causal effects of sIL6R on various diseases.
- Analysis of associations between genetically determined sIL6R and longevity traits (parental age at death).
- Gene-based association analysis using S-PrediXcan with GTExV7 tissue expression data.
Main Results:
- Inverse associations were found between sIL6R and rheumatoid arthritis, atrial fibrillation, stroke, coronary artery disease, and abdominal aortic aneurysm.
- Positive associations were observed between genetically determined sIL6R levels and atopic dermatitis and asthma.
- sIL6R levels showed an association with increased longevity, suggesting a complex role in aging and health.
Conclusions:
- Genetically determined reduction in IL6 signaling, mediated by sIL6R, is associated with a lower risk of multiple cardiovascular diseases and increased longevity.
- This reduction in IL6 signaling comes at the cost of an increased risk for atopic conditions.
- The findings highlight the dual role of IL6 signaling in cardiovascular health, longevity, and atopic disease susceptibility.
Abstract:
Growing evidence suggests that inflammation is a significant contributor to different cardiovascular diseases (CVDs). Mendelian randomization (MR) was performed to assess the causal inference between plasma soluble IL6 receptor (sIL6R), a negative regulator of IL6 signaling, and different cardiovascular and immune-related disorders. Cis-MR with multiple instrumental variables showed an inverse association of sIL6R with rheumatoid arthritis, atrial fibrillation, stroke, coronary artery disease, and abdominal aortic aneurysm. However, genetically-determined sIL6R level was positively associated with atopic dermatitis and asthma. Also, sIL6R level was associated with longevity, as evaluated by parental age at death, a heritable trait. Gene-based association analysis with S-PrediXcan by using tissues from GTExV7 showed that IL6R tissue expression-disease pair associations were consistent with the directional effect of IL6 signaling identified in MR. Genetically-determined reduced IL6 signaling lowers the risk of multiple CVDs and is associated with increased longevity, but at the expense of higher atopic risk.
More Related Videos
10:21Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
Published on: September 20, 2024
08:51Author Spotlight: Integrated Multi-Omics Analysis for Unveiling Multicellular Immune Signatures in Clinical Heart Attack Cohorts
Published on: September 20, 2024
Related Concept Videos
The JAK-STAT Signaling Pathway
Psychoneuroimmunology: Cardiovascular Disease
A key area of focus in PNI is the relationship between stress and coronary...